AA
MRNA icon

ALPS Advisors’s Moderna MRNA Stock Holding History

ALPS Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Buy
+4,207
New +$218K ﹤0.01% 1087
2023
Q1 		– Sell
-2,406
Closed -$432K – 1093
2022
Q4 		$432K Sell
2,406
-10
-0.4% -$1.64K ﹤0.01% 634
2022
Q3 		$286K Buy
2,416
+81
+3% +$12.3K ﹤0.01% 879
2022
Q2 		$334K Sell
2,335
-24
-1% -$3.43K ﹤0.01% 719
2022
Q1 		$406K Buy
2,359
+1,492
+172% +$251K ﹤0.01% 472
2021
Q4 		$220K Buy
867
+18
+2% +$5.26K ﹤0.01% 869
2021
Q3 		$327K Buy
+849
New +$313K ﹤0.01% 838

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

ALPS Advisors's MRNA Position: Q2 2026 in Review

ALPS Advisors opened a new position in Moderna (MRNA) in Q2 2026: 4,207 shares worth $295K. The stake represents ﹤0.01% of the portfolio and ranks #1087 among its holdings. This is a return to the name: ALPS Advisors previously reported a position in MRNA as recently as Q4 2022.

ALPS Advisors first reported a position in MRNA in Q3 2021 and has held it in 7 quarters since. The position peaked at $432K in Q4 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • ALPS Advisors held 4,207 shares of Moderna worth $295K as of Q2 2026.
  • Moderna was a new ALPS Advisors position in Q2 2026.
  • Moderna made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1087 holding.
  • ALPS Advisors first reported a position in Moderna in Q3 2021 and has held it in 7 quarters since.
  • ALPS Advisors's Moderna position peaked at $432K in Q4 2022.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.